Cancer #27 lost the major pre-treatment clone that contained a MYO18B mutation after therapy, but gained p53 and CNTNAP5 mutations not present before therapy, alongside expansion of a minor pre-treatment clone. This evidence concerns the gene TP53 and cancer.